The FDA FAQ on Testing for SARS-CoV-2 provides more information on COVID-19 tests that are authorized for use with home specimen collection kits. Ensure appropriate follow-up, including on positive COVID-19 test results.

The FDA recommends to take at least two COVID-19 antigen tests 48 hours apart before ruling out a possible infection. Justin Paget/Getty Images We regularly answer frequently asked questions about

FAQs on Testing for SARS-CoV-2 This section is primarily intended for SARS-CoV-2 test developers. For general public and consumer FAQs on COVID-19, please see FDA's COVID-19 Frequently Asked

These frequently asked questions address specific animal food industry concerns related to Coronavirus Disease (COVID-19), the safety of the animal food supply, what to do if an employee tests positive, and how businesses can operate while employing COVID-19 social distancing guidelines.

Find the latest information: Aquatics FAQs Recommendations for Fully Vaccinated People COVID-19 Homepage. UPDATE. Given new evidence on the B.1.617.2 (Delta) (e.g., ibuprofen, naproxen) and worsening of COVID‑19. FDA external icon, the European Medicines Agency, the World Health Organization, and CDC are continuing to monitor the

The FDA authorized bivalent formulations of the Moderna and Pfizer-BioNTech COVID-19 vaccines for use as a single booster dose at least two months after completing

People age 12 and older are eligible for one. Updated vaccines that target the newest versions of COVID-19 (BA.4 and BA.5) are now available -- probably at a pharmacy near

COVID-19 Vaccines Authorized for Emergency Use or FDA-Approved Pfizer-BioNTech COVID-19 Vaccines Moderna COVID-19 Vaccines Janssen COVID-19 Vaccine Novavax COVID-19 Vaccine, Adjuvanted Fact sheets

85 rows · Jun 24, 2022 · A: Yes, section IV.B of the COVID-19 Transport Media Policy discusses policies specific to commercial manufacturers of certain types of viral transport media that are

You can report websites suspected of unlawfully selling medical products to the FDA through our website, by phone at 1-800-332-1088, or email to FDA-COVID-19-Fraudulent

Frequently Asked Questions from FTA Grantees Regarding Coronavirus Disease (COVID-19) These FAQs provide clarity regarding how COVID-19 preparations impact certain FTA requirements. They also contain recommendations from the Centers for Disease Control and Prevention (CDC) to help grantees and subgrantees prepare for COVID-19.